Johannesburg, South Africa, June 30, 2022 (GLOBE NEWSWIRE) — Republic of South Africa Medical Marijuana Dispensaries Acquisitions LLC (“RSAMMDA.LLC”) and Protext Mobility, Inc (OTC PINK: TXTM) are pleased to announce that its Chairman, Dr. Ahmed Jamaloodeen (Dr.J) has been given the great honor of being appointed Chairman of the National Council for Cannabis Products and All Native Flora. As the largest agricultural union, the President will represent and interact with all stakeholders including but not limited to government, local and international governments to establish a framework for the country of South Africa in with regard to cannabis and all the native flora.

Dr Jamaloodeen commented: “Last Thursday I had the great honor of accepting the appointment of Chairman of the National Commodity Board of Cannabis and Native Flora in South Africa. What full EU support means is empowerment. And now, with the acquisition complete, Protext has established management with the knowledge, relationships – government and otherwise, compliance, resources, facilities, biomass, human capital and infrastructure that are invaluable. The federally issued and published licenses we possess allow for the import, export, cultivation and cultivation of cannabis and hemp, research, testing, development of end products for global distribution, which should all to be used by Protext with the ultimate goal of commercializing the live plant extraction technology and bringing to market premium finished products. Having a technology that has been proven to increase bioavailability 10-15 times more is important. Further testing should be carried out over the next few weeks as we are in the process of bringing the kettle equipment back to the farm. Testing will focus on maximizing yield as well as testing various strains.

Dr.J continued, “As we have previously stated, but it bears repeating, we have entered into this transaction with Protext as we believe there are many synergies in enabling access to certain assets of our established business with Protext as well as the commercialization of Protext’s proprietary live plant extraction technology and processes within our existing hemp and cannabis infrastructure.Prior to the merger, Protext had collaborated with RSAMMD and Leeds Boerdery, in which the companies used Protext’s proprietary live plant extraction technology along with Kettle extraction equipment to perform a series of live cannabis extraction tests at New Castle Farm under license and permits issued by the federal government, with the goal of producing an emulsion rich in cannabinoids but with little or no conversion of THC-A into psychoactive THC. took a series of tests to prove that the Kettle system and extraction technologies did what they were supposed to do. As part of our previous investigations, various tests were carried out using live cannabis flowers and leaves, transformed into liquid emulsions supplied by the New Castle farm. Previously, it was hypothesized that processing live cannabis at lower temperatures would yield a rich nano-emulsion of phytocannabinoids while retaining the non-psychoactive precursor acid form (THC-A). Our investigations have conclusively demonstrated that full-spectrum cannabinoids can be extracted using the proprietary Kettle system, with minimal metabolic conversion, paving the way for the advancement of medical research using non-psychoactive cannabis. What also intrigued us were the results of previous research and clinical trials which showed that the Kettle System, when applied to other herbal medicines, can create a significantly more bioavailable extract (10-15x ) than a standard snippet. This means that our cannabis extract should be more potent while delivering a dose that could potentially last up to 24 hours in the bloodstream, which is consistent with previous clinical results using other herbal remedies. Medically, this opens the door to a range of natural pharmaceuticals derived from cannabis but at a fraction of the price and with potentially superior results. From a business perspective, an increase in bioavailability of this magnitude can be a game-changer for growers, as it could essentially increase net yield by a factor of 10-15 times per plant, per acre, per farm.

“All of this work was made possible by a federally issued license and permit to conduct cannabis research and testing at New Castle Farm, managed and monitored by Dr. idea of ​​commercializing proprietary extraction technology. By designing a way to extract phytocannabinoids without the metabolic conversion of THC-A, we can retain the entourage effect and full medical potential of cannabis, but without the psychoactive property delivered by THC. We believe that what we have just shown is a scientifically significant milestone and technological breakthrough of global significance and we look forward to moving to commercialization, which may include global licensing opportunities for further cultivation and extraction in the world. concluded the CEO of Protext, Mr. Du Plooy.

For media inquiries or further information, please contact
Dylon Du Plooy at: [email protected]
Dr J at: [email protected]

Follow us on :


RSAMMDA.LLC. is an acquisition-driven joint venture with two directors, Mr. Dylon Du Plooy and Dr. Ahmed Jamaloodeen (“Dr. J”). Mr. Du Plooy is a South African pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids. Dr. J operates the 5,000 hectare New Castle Farm as well as federal cannabis and hemp licenses issued by the South African government. Together, we partner with leading hospitals and universities around the world to advance the clinical benefits and applications of cannabinoids.

The founders of RSAMMDA.LLC are a group of doctors and pharmacists, and cannabis activists who have been at the forefront of medical cannabis legislation and the legalization of cannabis in South Africa, which has took place in September 2018. We are committed to advancing technology and scientific research that leads to a better quality of life for patients around the world.

About Protext (OTC PINK: TXTM)

Through its prior acquisitions, Protext has been engaged in the research, testing and development of highly bioavailable botanical products comprised of all-natural ingredients formulated for nutraceutical and pharmaceutical applications through the use of proprietary technology from extraction of living plants.

Safe Harbor Statement
This press release contains forward-looking statements based on current expectations or beliefs, as well as on a number of assumptions regarding future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions on which they are based are reasonable, we can give no assurance or guarantee that these expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words such as “may”, “will”, “should”, “could”, “expect”, “anticipate”, “estimate”, “believe”, ” intends” or “project” or the negative of these words or other variations of these words or comparable terminology. The reader is cautioned not to place undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including, but not limited to: adverse economic conditions, competition, federal, state and local government regulations adverse, international government regulations, insufficient capital, inability to complete research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements contained in this press release are not strictly historical, including statements regarding revenue projections, business strategy, prospects, objectives, future milestones, plans, intentions, objectives , future financial conditions, events subject to shareholder or other approval, or otherwise, with respect to future events, these statements are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update the information contained in the forward-looking statements. This press release should not be considered a general solicitation.

More Stories
Therma Bright provides update on the FDA-EUA application process